These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37365794)

  • 1. Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post-approval in Japan.
    Saito R; Miyazaki S
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01110. PubMed ID: 37365794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
    Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition.
    Tamura N; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):166-75. PubMed ID: 24737526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streamlining Considerations for Safety Measures: A Predictive Model for Addition of Clinically Significant Adverse Reactions to Japanese Drug Package Inserts.
    Watanabe T; Ambe K; Tohkin M
    Biol Pharm Bull; 2024; 47(3):611-619. PubMed ID: 38479885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
    Hirota S; Yamaguchi T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
    Nakayama H; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Feb; 33(1):45-52. PubMed ID: 31933266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
    Suzuki A; Sato H; Sasaki Y
    Clin Transl Sci; 2019 Sep; 12(5):505-512. PubMed ID: 31062933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics on Drug Safety Measures in Japan Stratified by System Organ Classes and Therapeutic Categories in Relation to the Approval Date.
    Hiramatsu A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2020 Nov; 54(6):1534-1540. PubMed ID: 32524501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
    Li X; Lin X; Ren H; Guo J
    J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the Addition of Information Regarding Clinically Significant Adverse Drug Reactions to Japanese Drug Package Inserts Using a Machine-Learning Model.
    Watanabe T; Ambe K; Tohkin M
    Ther Innov Regul Sci; 2024 Mar; 58(2):357-367. PubMed ID: 38135862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Management Plans: are they a tool for improving drug safety?
    Frau S; Font Pous M; Luppino MR; Conforti A
    Eur J Clin Pharmacol; 2010 Aug; 66(8):785-90. PubMed ID: 20577875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999-2019.
    Nakao M; Nakamura Y; Shimokawa M; Maeda H
    Int J Clin Pharm; 2023 Feb; 45(1):108-116. PubMed ID: 36323961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between Post-marketing Safety-related Regulatory Actions and Characteristics of New Drugs Approved in Japan between 2005 and 2016].
    Watanabe Y; Narukawa M
    Yakugaku Zasshi; 2022; 142(7):761-770. PubMed ID: 35781506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Drug Lag on New Drug Label Revisions.
    Kikuchi C; Murakami M; Shimomura H; Shimada S; Aoyama T
    Ther Innov Regul Sci; 2019 Jan; 53(1):138-145. PubMed ID: 29714601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.